• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型行为方法和实施科学可减轻脂蛋白(a)升高导致的心血管疾病遗传风险。

Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a).

机构信息

Faculty of Health Sciences, School of Psychology, Curtin University, Bentley.

Faculty of Health and Medical Sciences, School of Medicine, University of Western Australia, Perth.

出版信息

Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):174-180. doi: 10.1097/MED.0000000000000609.

DOI:10.1097/MED.0000000000000609
PMID:33395090
Abstract

PURPOSE OF REVIEW

Elevated lipoprotein(a) [Lp(a)] is a genetic trait that indicates higher risk of atherosclerotic cardiovascular disease (ASCVD). We review novel strategies to mitigate behavioural risk-factors in this genetic condition.

RECENT FINDINGS

Pharmacological and biological interventions are available for lowering Lp(a). However, the acceptability and feasibility of these approaches are questionable due to cost and lack of clinical evidence for their efficacy. A number of low-cost, minimal patient contact interventions are available for modifying behavioural risk-factors that are associated with increased risk of ASCVD familial hypercholesterolaemia and diabetes. These include lifestyle interventions designed to improve diet and physical activity. These interventions may be particularly important among individuals with elevated Lp(a) to manage their higher risk of diabetes and ASCVD. The following article outlines recent research that has examined such low-cost, minimal patient contact interventions.

SUMMARY

The current research indicated that such interventions, which are grounded in psychological theory, can assist individuals to improve their diet and physical activity. These findings have implications for developing and implementing similar interventions for individuals with elevated Lp(a), so as to assist in reducing behavioural risk-factors associated with ASCVD.

摘要

目的综述

脂蛋白(a)升高[Lp(a)]是一种遗传特征,表明患动脉粥样硬化性心血管疾病(ASCVD)的风险更高。我们综述了减轻这种遗传情况下行为风险因素的新策略。

最近的发现

目前已有降低 Lp(a)的药物和生物学干预措施。然而,由于成本问题以及缺乏疗效的临床证据,这些方法的可接受性和可行性值得怀疑。有许多低成本、患者接触最少的干预措施可用于改变与 ASCVD 家族性高胆固醇血症和糖尿病风险增加相关的行为风险因素。其中包括旨在改善饮食和身体活动的生活方式干预措施。对于 Lp(a)升高的个体来说,这些干预措施可能特别重要,有助于管理其糖尿病和 ASCVD 的高风险。本文概述了最近研究,该研究检查了这些低成本、患者接触最少的干预措施。

总结

目前的研究表明,这些基于心理理论的干预措施可以帮助个体改善饮食和身体活动。这些发现对于为 Lp(a)升高的个体制定和实施类似的干预措施具有重要意义,有助于降低与 ASCVD 相关的行为风险因素。

相似文献

1
Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a).新型行为方法和实施科学可减轻脂蛋白(a)升高导致的心血管疾病遗传风险。
Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):174-180. doi: 10.1097/MED.0000000000000609.
2
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.脂蛋白(a)与动脉粥样硬化性心血管疾病:当前认识与未来展望。
Cardiovasc Drugs Ther. 2019 Dec;33(6):739-748. doi: 10.1007/s10557-019-06906-9.
3
Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).描述涉及脂蛋白(a)的家族性高胆固醇血症的新药理学策略。
Eur Heart J. 2017 Dec 21;38(48):3555-3559. doi: 10.1093/eurheartj/ehx546.
4
To test, or not to test: that is the question for the future of lipoprotein(a).检测还是不检测:这是脂蛋白(a)未来面临的问题。
Expert Rev Cardiovasc Ther. 2019 Apr;17(4):241-250. doi: 10.1080/14779072.2019.1596799. Epub 2019 Apr 3.
5
In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.在儿科家族性高胆固醇血症中,脂蛋白(a)比 LDL-C 更能预测家族成员心血管疾病的早发。
J Clin Lipidol. 2018 Nov-Dec;12(6):1445-1451. doi: 10.1016/j.jacl.2018.07.014. Epub 2018 Jul 31.
6
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.家族性高胆固醇血症和脂蛋白(a)升高:双重遗传性风险和新的治疗机会。
J Intern Med. 2020 Jan;287(1):2-18. doi: 10.1111/joim.12981.
7
Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.在家族性高胆固醇血症的级联检测中测量脂蛋白(a)的价值。
J Am Coll Cardiol. 2019 Mar 12;73(9):1029-1039. doi: 10.1016/j.jacc.2018.12.037.
8
Lipoprotein(a) and mortality-a high risk relationship.脂蛋白(a)与死亡率——高风险关系
Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):13-19. doi: 10.1007/s11789-019-00095-3.
9
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.家族性高胆固醇血症患者的心血管疾病预防:PCSK9 抑制剂的作用。
Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23.
10
Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?家族性高胆固醇血症患者心血管疾病风险评估中是否应考虑脂蛋白(a)?
Curr Pharm Des. 2018;24(31):3665-3671. doi: 10.2174/1381612824666181010150958.

引用本文的文献

1
Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a).对高脂蛋白(a)先证者亲属进行脂蛋白(a)升高的级联检测。
Am J Prev Cardiol. 2022 Apr 21;10:100343. doi: 10.1016/j.ajpc.2022.100343. eCollection 2022 Jun.